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ABSTRACT
Background: Fetal alcohol spectrum disorders (FASDs) are condi-
tions characterized by physical anomalies, neurodevelopmental ab-
normalities, and neurocognitive deficits, including intellectual,
executive, and memory deficits. There are no specific biological
treatments for FASDs, but rodent models have shown that prenatal
or postnatal choline supplementation reduces cognitive and behav-
ioral deficits. Potential mechanisms include phospholipid produc-
tion for axonal growth and myelination, acetylcholine enhancement,
and epigenetic effects.
Objective: Our primary goal was to determine whether postnatal
choline supplementation has the potential to improve neurocogni-
tive functioning, particularly hippocampal-dependent memory, in
children with FASDs.
Design: The study was a double-blind, randomized, placebo-
controlled pilot trial in children (aged 2.5–5 y at enrollment) with
FASDs (n = 60) who received 500 mg choline or a placebo daily
for 9 mo. Outcome measures were Mullen Scales of Early Learn-
ing (primary) and the elicited imitation (EI) memory paradigm
(secondary).
Results: The administration proved feasible, and choline was well
tolerated. Participants received a dose on 88% of enrolled days. The
only adverse event linked to choline was a fishy body odor. Choline
supplementation improved the secondary outcome (EI) only after
immediate recall performance was controlled for, and the outcome
was moderated by age. The treatment effect on EI items recalled
was significant in the younger participants (2.5- to#4.0-y-olds); the
young choline group showed an increase of 12–14 percentage points
greater than that of the young placebo group on delayed recall
measures during treatment. However, there was a marginal baseline
difference in delayed item recall between the young choline and
placebo groups as well as a potential ceiling effect for item recall,
both of which likely contributed to the observed treatment effect.
We also observed a trend toward a negative effect of choline sup-
plementation on the immediate EI recall of ordered pairs; the young
placebo group showed an increase of 8–17 percentage points greater
than that of the choline group during treatment. There was an in-
verse relation between choline dose (in mg/kg) and memory im-
provement (P = 0.041); the data suggest that weight-adjusted doses
may be a better alternative to a fixed dose in future studies. Limi-
tations included trend-level baseline differences in performance, the
post-hoc determination of age moderation, and potential ceiling
effects for the memory measure.
Conclusions: This pilot study suggests that an additional evaluation
of choline supplementation as an intervention for memory function-
ing in children with FASDs is warranted. The observed interaction
between age and choline’s effect on EI suggests that potential sen-
sitive periods should be considered in future work. This trial was
registered at clinicaltrials.gov as NCT01149538. Am J Clin Nutr
2015;102:1113–25.
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INTRODUCTION
Fetal alcohol spectrum disorders (FASDs)9 represent a pro-
found public health crisis with prevalence estimates as high as
2–5% in the United States and Western Europe (1). Individuals
with fetal alcohol syndrome (FAS), which is the most severe
form of FASD, have high rates of intellectual impairment (2, 3).
Individuals with other FASDs, including partial fetal alcohol
syndrome (pFAS) and alcohol-related neurodevelopmental dis-
order, are seriously affected by deficits in attention, executive
functioning, and memory among other skills (4–6). Currently,
there have been very few cognitive and behavioral interventions
for FASDs (7–9), and there are no biological treatments.
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Preclinical models of FASDs have consistently identified the
hippocampus as particularly vulnerable to insult, and numerous
experiments revealed memory deficits in animals exposed to
alcohol prenatally (10–12). Studies of memory in children with
prenatal alcohol exposure also have shown deficits in hippo-
campus-mediated encoding processes (13, 14). In normally de-
veloping animals, choline supplementation during gestation and
the early postnatal period enhances performances on measures
of cognition including memory (15–17). In animals exposed
prenatally to alcohol, there has been strong evidence that dietary
choline supplementation prenatally during hippocampal neuro-
genesis and postnatally, as late as days 21–30 during rapid
hippocampal differentiation in the rodent (equivalent to human
early childhood), attenuates memory and behavioral deficits that
are normally observed (18, 19). Improvements have been seen in
cognitive functions and behaviors that rely on the hippocampus
including visual-spatial learning, spatial reversal learning, and
fear conditioning (20).
At the time of the writing of this article, there were no pub-
lished human trials of choline supplementation in FASDs to our
knowledge. We previously reported on a pilot study that ex-
amined the safety and tolerability of choline in children with
FASDs (n = 20) (21), and in the current study, we report on the
results of the completed trial that included the participants from
the previous pilot study. The trial enrolled 60 participants with
FASDs who were aged 2.5–5 y. The goals of the overall study
were to establish the feasibility of long-term choline supple-
mentation in a large sample of children with FASDs and, be-
cause of compelling basic science findings, to examine the
efficacy of choline as a neurocognitive treatment by specifi-
cally targeting behaviors dependent on hippocampal integrity.
Thus, we hypothesized that choline would improve perfor-
mances on a hippocampus-dependent memory task [elicited
imitation (EI)] and, more generally, on a test of global cogni-
tive functioning.
METHODS
The study was a randomized, double-blind, placebo-controlled
trial conducted at the University of Minnesota from June 2010 to
May 2014. Participants underwent an informed consent process,
and all procedures were approved by the University’s In-
stitutional Review Board. Additional oversight was provided by
the University’s clinical trial monitoring program as well as an
independent Data Safety Monitoring Board. Choline was ad-
ministered under the Federal Drug Administration Investiga-
tional New Drug application 107085. The trial was registered at
clinicaltrials.gov as NCT01149538 on 21 June 2010 before the
first participant’s enrollment. A complete description of methods
and procedures was reported in Wozniak et al. (21).
Subjects
Children with FASDs (aged 2.5–5.0 y at enrollment) were
recruited from the University’s FASD Clinic and International
Adoption Clinic. Sixty children received the allocated in-
tervention (Table 1) of whom 85% (n = 51) completed the 9-mo
study (Figure 1).
Exclusion criteria were the presence of another developmental
disorder (e.g., autism, Down syndrome), neurologic disorder,
traumatic brain injury, or other medical condition that affects the
brain. Psychiatric comorbidity, such as attention-deficit hyper-
activity disorder or learning disorder, was not exclusionary be-
cause comorbidity is common with FASDs (22). All but one
participant (a twin born at 36 wk who weighed1360 g) had a birth
weight .1500 g.
TABLE 1






Age, y 3.79 6 0.802 3.92 6 0.76
Sex, n (%)
M 12 (39) 10 (35)
F 19 (61) 19 (65)
Racial categories, n (%)
White 16 (52) 9 (31)
Black or African American 5 (16) 9 (31)
American Indian/Alaska Native 4 (13) 7 (24)
Asian 1 (3) 1 (4)
More than one race 5 (16) 3 (10)
Ethnic category, n (%)
Hispanic or Latino 1 (3) 1 (3)
Not Hispanic or Latino 29 (94) 27 (93)
Unknown 1 (3) 1 (4)
Dysmorphic facial features, n (%)
Lip (score of 4 or 5) 16 (52) 10 (35)
Philtrum (score of 4 or 5) 13 (42) 9 (31)
Palpebral fissure (#10th percentile)3 21 (68) 20 (69)
$2 facial features present 20 (65) 17 (59)
Growth deficiency
(#10th percentile), n (%)
Height3 4 (13) 0 (0)
Weight 5 (16) 1 (3)
Deficient brain growth
(#10th percentile) OFC,3 n (%)
3 (10) 0 (0)
Alcohol exposure, n (%)
Alcohol confirmed 24 (77) 26 (90)
Alcohol suspected 7 (23) 3 (10)
Drug exposure, n (%)
Other drug exposure suspected 21 (68) 21 (72)
IOM diagnostic category, n (%)
FAS 5 (16) 5 (17)
Partial FAS 15 (48) 11 (38)
ARND 11 (36) 13 (45)
Baseline cognitive-functioning scores4
Mullen Visual Reception 41 6 12 44 6 16
Mullen Fine Motor 42 6 9 40 6 15
Mullen Receptive Language 41 6 9 40 6 12
Mullen Expressive Language 40 6 8 41 6 11
Mullen Early Learning Composite 83 6 14 84 6 21
1ARND, alcohol-related neurodevelopmental disorder; FAS, fetal alco-
hol syndrome; IOM, Institute of Medicine; OFC, occipital-frontal circum-
ference.
2Mean 6 SD (all such values).
3Data from the study baseline were missing from participants who were
uncooperative and from whom an accurate measure could not be obtained
for palpebral fissure length (choline: n = 3), height (choline: n = 1), and OFC
(choline: n = 1). Data acquired from previous clinical evaluations are in-
cluded for these participants.
4Data were missing for 2 participants (choline: n = 2) who were unable
to finish testing.
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To characterize the sample diagnostically, we applied modified
Institute of Medicine (IOM) criteria (23) to the growth, facial
dysmorphology, and alcohol-exposure data collected in the clinic
and during the baseline visit. Of 60 participants, 10 individuals
(17%) met the criteria for FAS; 24 individuals (40%) met criteria
for pFAS; and 24 individuals (40%) met criteria for alcohol-
related neurodevelopmental disorder (Table 1).
Because IOM criteria do not specifically characterize cognitive
functioning, we further applied CDC central nervous system
(CNS) criteria for FASDs (24) [see our previous article for details
(21)]. Nineteen participants (32%) met the CNS criteria for an
FASD diagnosis on the basis of deficient brain growth, whereby
15 subjects (25%) had global cognitive impairment (.2 SDs
below the average), and 57 subjects (95%) had deficits of.1 SD
in $3 domains (e.g., intellectual, language, motor, visual-
perceptual, adaptive functioning, and behavioral domains). One
participant (2%) was deficient in only one domain. Twenty-six
participants (43%) met $2 CNS criteria.
Eighty-three percent of subjects (n = 50) had confirmed prenatal
alcohol exposure, including a self-report by the biological mother
or social service records that indicated heavy maternal use during
pregnancy. Participants with maternal alcohol use at rank 3 or 4 in
the University of Washington diagnostic system (25) were in-
cluded. Ten participants had unconfirmed alcohol exposure, but
alcohol use was suspected, and all 10 subjects had dysmorphic
faces and cognitive deficits as previously defined. The 10 subjects
met the modified IOM criteria for FAS (n = 1) or pFAS (n = 9). In
42 cases, other prenatal drug use was suspected. There was no
difference in suspected drug use between the 2 treatment arms
(Table 1). In all cases, alcohol was the predominant substance of
abuse, and alcohol use was extensive.
Procedures
Participants received the supplement daily for 9 mo. The length
of the intervention was selected to measure the potential develop-
mental change in response to the treatment and to maintain a feasible
daily administration of the experimental agent in preschool-age chil-
dren, who are a group for whom supplementation can be challenging.
The study was designed to be completed in 2 phases. The
primary outcome assessed in the first phase was side effects or
adverse events, the results of which have been reported pre-
viously (21). The second phase was designed to further evaluate
safety and tolerability and to measure the effect of choline on
neurocognitive functioning. The primary outcome was an as-
sessment of global cognitive functioningwith the use of theMullen
Scales of Early Learning. The secondary outcome was an as-
sessment of hippocampal-dependent functionwith the use of the EI
memory task. Event-related potential datawere also collected as an
electrophysiological measure of brain functioning; however, event-
related potential results are not reported in the current article
because they were beyond the scope of the current report.
In-person assessments took place at the University of Minnesota
at baseline (before receiving the allocated intervention) and at 6 and
9mo. Phone visits occurred 2wk after baseline and thenmonthly to
monitor compliance and adverse events. The Mullen Scales of
Early Learning were administered at baseline and at 9 mo. EI was
administered at all 3 visits (at baseline and at 6 and 9 mo).
Allocated intervention
Participants were randomly assigned in a one-to-one allo-
cation ratio with the use of preprepared computerized block-
randomization schedules by the University’s Investigational Drug
FIGURE 1 Flowchart of the randomized clinical trial of postnatal choline supplementation.
CHOLINE SUPPLEMENTATION IN CHILDREN WITH FASD 1115
Services unit to receive 500 mg choline (1.25 g choline bi-
tartrate) or a placebo daily for 9 mo. A concealed allocation was
implemented, and the research team and participants were
blinded to group assignments. The allocated intervention was
supplied in coded light-blocking foil packets that contained
a powdered, fruit-flavored drink mix that was developed for the
study. Packet dosages and stability were evaluated with the use
of HPLC by an outside laboratory. The dosage was within 0.13%
of the target, on average, and stable (within 5.2% of target
dosage over the study duration). Parents were instructed to ad-
minister 1 dose/d by mixing it with 4 fl oz (118.3 mL) H2O.
Measures
Feasibility of choline supplementation
Compliance, fidelity, and adverse events were monitored via
calendar log sheets, dietary recalls, and serum choline concen-
trations. Parents used calendar log sheets to document the pro-
portion of the allocated intervention the children consumed each
day. If ,100% of the drink was consumed, the amount and
reason were recorded.
Detailed 24-h food recalls were administered at baseline and at
6 and 9 mo with the use of the automated self-administered 24-h
recall system (26) to evaluate the potential confounding influence
of changes in dietary choline intake. Dietary data were included
only if the parent recalled all meals and snacks from the 24-h
period (e.g., data were not included if the parent had no in-
formation about the child’s intake at school on that day).
Numbers of subjects are reported for all dietary intake data.
Families were instructed to refrain from adding dietary supple-
ments during the study, which was reinforced at all study visits
including phone visits.
Serum choline and betaine concentrations were measured at
baseline and at 6 and 9 mo. Parents were asked to administer the
allocated intervention 3 h before the scheduled blood draw
(venipuncture). Choline and betaine were assayed with the use of
liquid chromatography/electrospray ionization–isotope dilution
mass spectrometry (27).
A physician completed a physical examination at each in-
person visit, which included a review of major organ systems, to
assess adverse events. Adverse events were also monitored during
monthly phone visits. Changes in body or urine odor were moni-
tored because high serum choline concentrations have been asso-
ciated with fishy odor that is due to trimethylamine formation (28).
For a subsample, plasma was assayed for trimethylamine N-oxide
(TMAO) with the use of liquid chromatography/electronspray
ionization–isotope dilution mass spectrometry (29). The TMAO
assay was added midway through the study and was only done
on a random subset because of the cost. Compliance problems
with the administration of the allocated intervention were also
monitored monthly.
Mullen Scales of Early Learning (primary outcome)
The Mullen Scales of Early Learning (30) is a measure of
global cognitive development with the use of normative data from
birth to 68 mo of age. The measure assesses visual reception, fine
motor, receptive language, and expressive language abilities, and
yields t scores for each of these subtests with a mean 6 SD of
50 6 10 points. Subtest scores are summed and converted to an
Early Learning Composite, which is an age-scaled intelligence
quotient–like score with a mean 6 SD of 100 6 15 points.
EI (secondary outcome)
The EI paradigm assesses explicit memory ability in preverbal
children via the behavioral imitation of action sequences (31, 32).
This paradigm is a nonverbal analog to verbal memory report (33)
and requires support from the hippocampus (34). The paradigm
reflects normal developmental changes in memory ability within
the age range of the current study (35), is sensitive to neuro-
developmental disruption (36), and is predictive of later memory
abilities in school-age children (37). The task involves sets of toys
that are used in event sequences. Each sequence has a theme (e.g.,
going camping) and incorporates multiple toys that are used in
a prescribed sequence of 9 individual actions (e.g., baiting a hook,
catching a fish, and setting up a tent).
At each assessment, participants were shown 2 different 9-item
sequences. The procedure included a free play period and a recall
measure for each sequence. During free play, children were given
the toys to manipulate for 2 min. The free play provided a control
for spontaneous occurrences of target actions. An experimenter
modeled the event sequence twice with narration. The child was
directed to recall the event sequence in one of 2 conditions
(immediate or delayed). For immediate recall, the child was
asked to imitate the sequence after modeling. For delayed recall,
the toys were removed for 15 min after which the child was asked
to reproduce the sequence. Immediate recall provided a measure
of attention to the task and the encoding of items and sequences.
Delayed recall provided a measure of hippocampal-dependent
long-term memory. For each child, the 2 sequences were drawn
from a larger set of available sequences that were, in turn, coun-
terbalanced across conditions (immediate and delayed) and visits.
The production of individual items (e.g., baiting a hook,
catching a fish, and setting up a tent) and the correctly ordered
pairs of items (i.e., baiting the hook before catching the fish and
then setting up the tent) was assessed for both free play and the
recall for each condition (immediate and delayed). Sessions were
video recorded and scored offline by trained raters. Twenty percent
of the videos were coded by multiple raters to ensure reliability
(93%). The variables analyzed were the percentage of correct in-
dividual items produced (maximum: 9) and the percentage of
correctly ordered pairs produced (maximum: 8) for the following 3
conditions: free play, immediate recall, and delayed recall. Only
immediate and delayed recall measures were used in the current
study. Therewere no group differences in EI free -play performance.
Statistical analyses
Feasibility and tolerability analyses
The distributions of the compliance log-sheet variables were
nonnormal and leptokurtic, and therefore, medians and IQRs are
reported. Between-group comparisons of these variables were
conducted with the use of Mann-Whitney U tests. The distri-
bution of serum TMAO was also nonnormal at the 6- and 9-mo
visits, and medians and IQRs for TMAO are reported in addition
to the mean value for each visit. For between-group comparisons
of categorical variables, Fisher’s exact test was used because of
small cell sizes. The Freeman-Halton extension of the Fisher’s
exact test (38) was used for contingency tables that were larger
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than 2 3 2. t tests were used for between -group comparisons of
continuous variables.
Mixed-model specification
Growth curve analyses with the use of linear mixed models
were performed to test for treatment differences in growth tra-
jectories (intercepts, which represented baseline differences, and
slopes, which represented the differential change over time) for
the feasibility and neurocognitive data. The analyses, which
modeled fixed effects and random child-specific intercepts, were
conducted with the SAS (version 9.4) Proc Mixed procedure
(SAS Institute Inc.) with the use of a restricted maximum
likelihood estimation (REML). The REML with an estimated df
procedure (39) was used because data were not available for all
participants at each time point, and the REML yields valid
variable estimates with incomplete data without imputing
missing data or using list-wise deletion. The variables are esti-
mated under the assumption that the missing data could be ig-
nored (40), which was assumed in the current study. The
following 2 types of general linear mixedmodels (random-effects
models) were initially considered: 1) models with child-specific
intercepts only and 2) models with both child-specific intercepts
and child-specific slopes. Models were compared with the use of
the Akaike information criterion, which takes into account both
the degree of model fit to the data and the model complexity.
Intercept-only models were shown to have consistently better
Akaike information criterion values than the intercept and slope
models did. Longitudinal analyses were conducted as intention-
to-treat analyses with all available data from participants who
received the allocated treatment (choline: n = 31; placebo: n = 29)
included in the analyses independent of their completion of the
study and compliance during the study (Figure 1).
For data collected at 3 visits (e.g., EI memory data), the linear
slope term was specified to estimate the growth trajectory across
3 time points (time 0: baseline; time 1: 6-mo visit; time 1.5:
9-mo visit). The intercept represents the estimated value at
baseline (time 0) in the growth curves, and the linear slope
represents the change in outcome over the time during treatment,
with one unit of time along the x-axis representing 6 mo of
treatment. For data collected at 2 visits (e.g., Mullen Scales),
the linear slope term was specified across 2 time points (time 0:
baseline; time 1: 9-mo visit).
Curve fit
Before the main effects of treatment were tested, unconditional
growth-curve analyses were performed to determine whether the
general growth trajectory for each longitudinal outcome was
linear or nonlinear (quadratic) regardless of the treatment group
(Supplemental Equation 1). Unconditional analyses (which did
not include the treatment group in the model) gave growth-curve
estimates for the entire sample. The appropriate slope (linear or
quadratic) was tested in the conditional analyses (with the
treatment group added to the analysis) to examine treatment-
group differences (Supplemental Equations 2–6). All reported
longitudinal analyses tested for the linear change unless other-
wise specified.
Tests for demographic moderation of main treatment effects
For the neurocognitive data (Mullen Scales and EI), 2 sets of
conditional longitudinal analyses were performed to test the
treatment effect. First, the main effect of treatment was examined
without demographic covariates or moderators (Supplemental
Equations 2 and 4). Second, 3-way interactions between the
treatment group and age, race, or FASD diagnosis were exam-
ined to test for moderation (i.e., whether the association between
treatment and neurocognitive outcomes differed as a function of
these subject variables) (Supplemental Equations 3 and 5). For
each significant 3-way interaction, simple slope analyses were
completed to evaluate the change in performance over time for
each value of the moderator (41).
Assessment of main treatment effects with and without
demographic covariates
Variables were included as covariates if there was a difference
in the group distribution even after random assignment and if
there was a potential association with the outcome measures.
Covariates included age, race, and FASD diagnosis. Because
dysmorphic facial features, growth deficiency, deficient brain
growth, and alcohol exposure form the basis of an FASD di-
agnosis, these variables were not included again as independent
covariates. The remaining demographic characteristics were not
included as covariates because they were very closely matched or
had no known association with the outcome measures. Analyses
are presented with and without the covariates included in the
model (Supplemental Equations 5 and 6). Effect sizes are pre-
sented for both the unadjusted (no covariates) and adjusted (with
covariates) models.
Immediate EI performance as a covariate
For EI, the hypothesis was that choline would improve the
performance on the delayed recall condition because it depends
on hippocampal integrity. Choline’s effects in preclinical models
have been predominantly on the developing hippocampus
(18–20). Growth-curve analyses were completed for a delayed
performance with the corresponding immediate condition per-
formance included as a covariate in the model (Supplemental
Equations 4–6 and Supplemental Equation 7). The child’s
immediate performance represents the ability to attend to the
stimuli and encode a sequence and was included in the models
to control for the variability introduced by these nondelay–related
characteristics of the child’s performance.
Effect size
For significant linear slope results, effect sizes (Cohen’s
d values) were determined by first standardizing the change
scores (the difference between the estimated mean baseline and
9-mo follow-up scores) by the SD of the raw baseline scores for
each treatment group (42). The difference between the stan-
dardized change scores for the 2 treatment groups was calcu-
lated. Effect sizes for significant moderators were determined by
calculating the difference between the effect for the placebo and
treatment groups for each value of the moderator.
RESULTS
Feasibility of choline supplementation: compliance, fidelity,
and adverse events
Completed log sheets were returned by 95% of participants.
Participants reportedly received a partial dose (at least one-quarter)
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or a full dose of the allocated intervention on 88% (IQR: 69–
96%) of the days in the study. Reported days that participants
received a dose did not differ between the 2 arms [choline:
median: 87% (IQR: 72–93%); placebo: median: 90% (IQR:
69–96%); P = 0.306]. The 24-h dietary recall data revealed no
differences in dietary choline intake across the 2 arms at any
point (Table 2). Significant increases in serum choline (102%)
and betaine (106%) concentrations occurred with choline
supplementation (Table 2).
A fishy odor was the only adverse event that occurred dif-
ferentially in the choline arm during treatment (Table 3). This
odor was due to trimethylamine formation by gut bacteria;
trimethylamine is oxidized in the liver to form TMAO. During
treatment, serum TMAO concentrations reached 22-times higher
in the choline arm than in the placebo arm (Table 2; 6 mo). A
fishy odor was episodically noticeable to parents (mostly when
changing clothes, bathing, or toileting) but was not noticeable to
the research assistant who administered the outcome measures.
Physical examination results, including height, weight, and
blood pressure, remained consistent for both groups throughout
the duration of the study (Table 2).
Mullen Scales of Early Learning (primary outcome
measure)
Intercept (baseline difference) and linear slope (change over
time) results were examined to test the main effect of treatment
on the Mullen Scales (Supplemental Equation 2). None of the
intercept or linear slope results reached significance, which in-
dicated that there were no differences between the 2 treatment
arms before treatment or during treatment of the Mullen Early
Learning Composite or of any of the subscales (Table 2). None
of the 3-way interactions used to test moderation for the main
effect of treatment on the linear slope reached significance for
the Mullen Scales (Supplemental Equation 3).
The Mullen Early Learning Composite was correlated (with
age controlled for) with EI delayed performance for items (partial
r = 0.56, P , 0.001) and ordered pairs (partial r = 0.47, P ,
0.001) at baseline but not at the 9-mo visit (P . 0.17 for all). In
other words, the Mullen scales and EI measures similarly re-
flected the participant’s level of functioning at baseline, but the 2
measures were differentially responsive to the intervention.
EI (secondary outcome measure)
Intercept and linear slope results were examined to test the
main effect of treatment on the growth trajectory of EI (items and
ordered pairs; Supplemental Equation 4). For the whole sample,
none of the intercept or linear slope results reached significance
for delayed recall (items or ordered pairs), which indicated that
there were no differences between the 2 arms (choline compared
with placebo) before treatment or during treatment of EI items
(estimated means for choline at baseline: 74%; at 6 mo: 81%;
and at 9 mo: 84%; estimated means for the placebo at baseline:
79%; at 6 mo: 83%; and at 9 mo: 85%). There were no differ-
ences for ordered pairs (estimated means for choline at baseline:
41%; at 6 mo: 52%; and at 9 mo: 58%; estimated means for the
placebo at baseline: 44%; at 6 mo: 52%; and at 9 mo: 57%).
Thus, for the whole sample, there was not a significant effect of
choline on EI delayed memory performance).
Race and FASD diagnosis as potential moderators of choline’s
effects on EI
To examine whether the treatment effect on EI delayed
recall was moderated by race or FASD diagnosis, 3-way in-
teractions for the linear slope were examined (Supplemental
Equation 5). None of the analyses reached significance, which
showed that the treatment effect on delayed recall did not
differ between children of different races or with different
FASD diagnoses.
Age as a moderator of choline’s effects on EI
Because preclinical data showed that early choline supple-
mentation in prenatally exposed animals is associated with
greater cognitive improvements than later supplementation is
(43), we hypothesized that age would be an important factor in
the human response to choline supplementation [the potential
interaction with agewas discussed in our earlier article on the first
pilot study (21)]. To examine whether the treatment effect on
delayed EI performance was moderated by age, 3-way in-
teractions between the treatment arm, age at baseline (as a con-
tinuous variable), and either the intercept or linear slope were
examined on EI delayed performance (items and ordered pairs).
Immediate (nondelayed) performancewas included as a covariate
(Supplemental Equation 5). The intercept was significant for
items [g = 11.60 (95% CI: 0.23, 22.98), t(114) = 2.02, P =
0.046] but not for ordered pairs [g = 3.91 (95% CI: 26.74,
14.56), t(118) = 0.73, P = 0.469]. The linear slope was also
significant for items [g = 210.76 (95% CI: 220.41, 21.10),
t(83.1) = 22.21, P = 0.030] but not for ordered pairs [g =
24.28 (95% CI: 213.59, 5.03), t(84.5) = 20.91, P = 0.363].
In summary, the group difference (choline compared with
placebo) in the rate of EI improvement over time differed
depending on the child’s age.
Age as a moderator of choline’s effects on EI with the use of
split-age groups
To more easily illustrate the moderating role of age on the
treatment effect and to gain an understanding of effect sizes, the
sample was split into 2 groups on the basis of the median age as
follows: a younger group (n = 30; placebo: n = 13; choline: n =
17) consisting of 2.5- to #4.0-y-olds and an older group con-
sisting of .4.0–5.0-y-olds (n = 30; placebo: n = 16; choline: n =
14). Three-way interactions were examined between the treat-
ment arm, age group, and either the intercept or linear slope for
delayed EI performance (items and ordered pairs; Supplemen-
tal Table 1 and Supplemental Equation 5). In the model for
items, there was a trend-level 3-way interaction between the
treatment group, age group, and linear slope [g = 214.75 (95%
CI: 230.38, 0.88), t(84.9) = 21.88, P = 0.064] but not for the
intercept [ g = 15.52 (95% CI: 23.20, 34.25), t(109) =1.64, P =
0.103]. For ordered pairs, there was a trend-level 3-way in-
teraction between the treatment group, age group, and linear
slope [g =213.68 (95% CI:228.89, 1.52), t(89.1) =21.79, P =
0.077] but not for the intercept [g = 8.95 (95% CI: 28.43,
26.34), t(117) = 1.02, P = 0.310]. As in the previous evaluation,
age appeared to play a role in the response to choline in terms of
the rate of improvement in EI delayed performance.
Figure 2 shows the estimated growth curves for the treatment
arms by age group for EI delayed recall (items and ordered
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TABLE 2
Results of growth-curve analyses that examined treatment-group differences in dietary choline intake, serum choline, physical examination results, and
Mullen Early Learning Scales by treatment arm1
Unadjusted values Growth-curve analyses, g 6 SE; P




choline vs. placebon Mean 6 SD n Mean 6 SD
Dietary choline, mg/d 211.29 6 23.87; 0.637 26.87 6 21.58; 0.751
Baseline 30 177 6 88 23 195 6 60
6 mo 18 231 6 99 21 221 6 104
9 mo 23 194 6 86 18 223 6 86
Serum choline, mM 20.25 6 0.82; 0.766 4.77 6 0.75; ,0.0001*
Baseline 22 6.53 6 1.62 23 7.20 6 1.51
6 mo 21 13.18 6 4.15 17 7.38 6 1.68
9 mo 20 13.23 6 4.19 18 7.16 6 1.68
Serum betaine, mM 20.78 6 8.60; 0.928 28.70 6 5.69; ,0.0001*
Baseline 22 42.96 6 16.64 23 48.91 6 9.79
6 mo 21 85.27 6 39.07 17 50.92 6 17.45
9 mo 20 88.83 6 50.85 18 50.38 6 17.26
TMAO,2 mM 1.89 6 17.81; 0.916 298.34 6 42.84; 0.033*
Baseline 7 2.87 6 1.94 6 0.98 6 0.66
6 mo 7 70.73 6 68.94 6 3.22 6 1.51
9 mo 5 29.34 6 21.57 5 4.94 6 7.39
Height z score 20.49 6 0.23; 0.038* 20.06 6 0.06; 0.322
Baseline 30 20.35 6 0.89 29 0.12 6 0.86
6 mo 20 20.20 6 0.85 18 0.29 6 0.76
9 mo 25 20.19 6 0.86 22 0.35 6 0.92
Weight z score 20.43 6 0.27; 0.114 0.04 6 0.04; 0.319
Baseline 31 20.14 6 1.18 29 0.29 6 0.81
6 mo 26 0.11 6 1.21 24 0.32 6 0.80
9 mo 26 0.12 6 1.25 25 0.31 6 0.80
Blood pressure, mm Hg 2.46 6 2.48; 0.323 21.60 6 2.46; 0.515
Systolic
Baseline 27 103 6 11 28 101 6 9
6 mo 23 102 6 8 24 100 6 12
9 mo 23 100 6 8 24 100 6 7
Diastolic 2.44 6 2.71; 0.368 23.83 6 2.56; 0.137
Baseline 27 63 6 14 28 61 6 10
6 mo 23 61 6 12 24 62 6 7
9 mo 23 60 6 8 24 64 6 9
Mullen Early Learning Scales score
Early Learning Composite 21.82 6 4.73; 0.701 20.36 6 3.09; 0.908
Baseline 29 83.2 6 13.7 29 84.3 6 21.4
9 mo 26 87.1 6 16.4 25 89.6 6 21.6
Visual Reception 23.26 6 3.69; 0.381 20.30 6 2.98; 0.920
Baseline 29 41.2 6 11.8 29 44.4 6 16.2
9 mo 26 43.5 6 10.8 25 47.0 6 13.9
Fine Motor 1.34 6 3.30; 0.69 20.67 6 2.69; 0.805
Baseline 29 42.0 6 9.3 29 40.1 6 15.0
9 mo 26 44.4 6 10.1 25 43.3 6 15.8
Receptive Language 0.44 6 2.88; 0.879 20.04 6 2.19; 0.984
Baseline 29 40.6 6 9.4 29 39.8 6 12.4
9 mo 26 42.2 6 10.8 25 41.8 6 12.3
Expressive Language 21.31 6 2.57; 0.614 0.08 6 2.72; 0.978
Baseline 29 40.3 6 8.5 29 41.2 6 10.8
9 mo 26 42.6 6 10.3 25 44.2 6 10.3
1Longitudinal analyses with linear mixed models with the use of restricted maximum likelihood estimations were used to compare differences in growth
curves between treatment groups (Supplemental Equation 2). For the growth-curve analyses, the estimated intercept column contains comparisons of baseline
values (time 0), and the estimated linear slope column contains comparisons of change over time including baseline (time 0), 6 mo (time 1), and 9 mo (time
1.5). For Mullen Scales, the time included baseline (time 0) and 9 mo (time 1). *P , 0.05.
2TMAO, trimethylamine N-oxide. The slope term reported for TMAO was quadratic and represented a significant nonlinear change. Median (IQR) values for
TMAO (mM) were as follows—at baseline: choline group, 2.90 mM (0.60–4.60 mM); placebo group, 1.00 mM (0.28–1.60 mM); at 6 mo: choline group, 38.3 mM
(13.50–150.70 mM); placebo group, 3.30 mM (2.08–4.05 mM); and at 9 mo: choline group, 40.40 mM (6.25–46.90 mM); placebo group, 1.50 mM (1.15–10.45 mM).
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pairs) while controlling for immediate performance. There was
a marginal intercept (baseline) difference between treatment
arms and age groups for individual items during the delayed EI
condition whereby the young age group, particularly the young
choline group, performed lower by chance. This difference in
intercepts was not likely due to dietary choline because there
was no difference in dietary choline intake at baseline between
the young choline group (35% of whom met adequate intake)
and the young placebo group (40% of whom met adequate in-
take) (P = 0.807).
During treatment, the largest improvement in delayed EI
performance was in the young choline group. Post hoc analyses
revealed significant differences in the simple slopes for both
delayed items and ordered pairs between treatment groups
(choline compared with placebo) for the young-age group but not
for the old-age group (Table 4). The simple slope values esti-
mated the change over 6 mo (from times 0 to 1). The change
over 9 mo of treatment was computed as 1.5 times the simple
slope. For delayed items, the young choline group showed an
increase of 21% over 9 mo of treatment compared with 7% in
the young placebo group (Table 4). For delayed ordered pairs,
the change was 28% in the young choline group compared with
16% in the young placebo group (Table 4). Effect sizes were
large for both outcome measures in the young group.
Evaluation of demographic covariates
Race and FASD diagnosis were examined as potential con-
founding variables in the model with age as a moderator to
determine whether the association between the treatment group
and linear slope in the young group was altered by these variables
(Supplemental Equation 6). With race and FASD diagnosis in-
cluded as covariates, the adjusted effect size for the linear slope
in the young group for delayed EI items was d = 0.58 (un-
adjusted effect size: d = 0.54) and, for delayed EI ordered pairs,
was d = 0.42 (unadjusted effect size: d = 0.50).
TABLE 3
Number of participants reporting symptoms at baseline and number reporting new symptoms (adverse events that were
not present at baseline) at least once during the course of treatment1
Choline (n = 31) Placebo (n = 29) P (Fisher’s exact test)
Administration problems with the supplement, n (%)
Baseline — — —
New symptoms during treatment 13 (42) 12 (41) 1.000
General health, n (%)
Baseline 7 (23) 3 (10) 20.302
New symptoms during treatment 8 (28) 5 (18) 0.530
Skin, n (%)
Baseline 9 (29) 15 (52) 0.113
New symptoms during treatment 4 (14) 4 (14) 1.000
Ear, nose, and throat, n (%)
Baseline 1 (3) 3 (10) 0.346
New symptoms during treatment 1 (4) 0 (0) 1.000
Cardiovascular, n (%)
Baseline 2 (7) 2 (7) 1.000
New symptoms during treatment 1 (3) 0 (0) 1.000
Respiratory, n (%)
Baseline 5 (16) 10 (35) 0.139
New symptoms during treatment 5 (17) 4 (14) 1.000
Gastrointestinal, n (%)
Baseline 14 (45) 12 (41) 0.800
New symptoms during treatment 9 (31) 7 (25) 0.770
Fishy body odor, n (%)
Baseline 0 (0) 0 (0) 1.000
New symptoms during treatment 15 (52) 1 (4) ,0.001*
Genitourinary, n (%)
Baseline 6 (19) 2 (7) 0.257
New symptoms during treatment 3 (10) 8 (29) 0.103
Musculoskeletal, n (%)
Baseline 3 (10) 7 (24) 0.175
New symptoms during treatment 0 (0) 0 (0) 1.000
Neurologic, n (%)
Baseline 15 (48) 11(38) 0.446
New symptoms during treatment 6 (21) 4 (14) 0.730
Allergy, n (%)
Baseline 7 (23) 10 (35) 0.394
New symptoms during treatment 0 (0) 2 (7) 0.237
Other, n (%)
Baseline 13 (42) 9 (31) 0.431
New symptoms during treatment 8 (28) 13 (46) 0.175
1During treatment, sample sizes were as follows: choline group: n = 29; placebo group: n = 28. *P , 0.05.
1120 WOZNIAK ET AL.
Alternate analysis without controlling for immediate EI
performance
The 3-way interaction between the age group, treatment group,
and growth curve for delayed EI performance was also examined
without controlling for immediate recall performance (Supple-
mental Equation 3). Results did not reach significance for any of
the growth-curve variables for the delayed performance of items
[intercept: g = 10.51 (95% CI: 210.98, 32.01), t(105) = 0.97,
P = 0.334; slope: g = 212.46 (95% CI: 228.56, 3.63), t(98.3) =
21.54, P = 0.128] or ordered pairs [intercept: g = 0.86 (95% CI:
219.11, 20.84), t(115) = 0.09, P = 0.931; slope: g = 27.50
(95% CI: 223.73, 8.37), t(98.8) = 20.94, P = 0.351]. In other
words, choline’s effect of improving delayed EI performance
was evident only when nondelay characteristics of the child’s
performance were controlled for.
Additional analyses of immediate EI performance
Growth trajectories for immediate EI performance are pre-
sented by age group and treatment arm in Figure 3 (Sup-
plemental Equation 3). Choline was not associated with
improvement in the immediate condition for items [intercept:
g =211.06 (95% CI:232.31, 10.19), t(105) =21.03, P = 0.304;
slope: g = 3.94 (95% CI: 213.19, 21.08), t(86.6) = 0.46, P =
0.649]. There was a trend toward significance in the 3-way in-
teraction for ordered pairs in the immediate condition (intercept:
g =219.14 (95% CI: 240.43, 2.15), t(119) =21.78, P = 0.078;
slope: g = 17.23 (95% CI: 20.97, 35.42), t(93.2) = 1.88, P =
0.063]. Post hoc analyses revealed a significant difference in the
simple slopes for immediate ordered pairs between treatment
groups (choline compared with placebo) for the young-age group
but not for the old-age group (Table 4). The young choline group
showed less improvement for ordered pairs, with an increase of
13% over 9 mo compared with 30% in the young placebo group.
Last, to put these results in context, immediate and delayed
performances were correlated at the baseline visit (items: partial
r = 0.59, P , 0.001; ordered pairs: partial r = 0.60, P , 0.001)
and at 6 mo (items: partial r = 0.61, P , 0.001; ordered pairs:
partial r = 0.55, P = 0.001) but not at 9 mo (items: partial r =
0.15, P = 0.322; ordered pairs: partial r = 0.26, P = 0.074) while
controlling for age. EI delayed and immediate performances
were correlated at baseline and 6 mo, but the 2 measures were
differentially responsive to the intervention and were no longer
correlated at 9 mo.
Average daily choline dose
The association between the average daily choline dose and EI
delayed recall was examined in the choline arm. To estimate the
mean choline dose received throughout the study, the full dose
(500 mg) was corrected for the percentage of days participants
received any supplement on the basis of parent-report log sheets.
The corrected dose was divided by the child’s weight at baseline
to yield the average daily choline dose received per kilogram of
body weight (mg/kg).
Because of the interaction between the treatment arm and age
on EI performance, age was included as a covariate in the dosage
analyses. EI immediate recall performance was also included as
a covariate (Supplemental Equation 7). Linear slope results were
significant for the choline dose (mg/kg) on EI delayed recall for
items [g =20.82 (95% CI:21.60,20.04), t(34.9) =22.13, P =
0.041] but not for ordered pairs [g = 20.30 (95% CI: 21.10,
0.49), t(36.6) = 20.77, P = 0.446]. Intercept results for the
choline dose (mg/kg) did not reach significance for EI items
(P = 0.152) or for ordered pairs (P = 0.343). Figure 4 depicts this
linear association between the dose (divided into quartiles) and
EI delayed performance. Subjects in the lowest quartile (i.e., the
lowest mg $ kg21 $ d21) showed greater improvement of de-
layed recall for items (21%) than subjects in the highest quartile
did (22%).
Finally, the association between the choline dose and presence
of fishy odor was examined. The prevalence of fishy odor was
greater in the highest quartile for choline dose (100% of subjects
reported a fishy odor at some point during the 9 mo) than in the
lower 3 quartiles for choline dose (42% of subjects reported
a fishy odor) (P = 0.020). There were no differences in the
presence of a fishy odor between the lowest 3 quartiles for
choline dose (Figure 5).
DISCUSSION
This pilot study represents an initial evaluation of the potential
efficacy of choline as a cognitive intervention in FASDs. As in our
previous study (21), choline had high tolerability and was as-
sociated with no serious adverse events at 500 mg/d in 2–5-y-olds
with FASDs. The study evaluated choline’s effects on cognition
in a randomized, double-blind, placebo-controlled trial. Age-
dependent improvements were seen on a hippocampus-dependent
memory task. In this small pilot sample, younger participants
FIGURE 2 Treatment effect on elicited imitation delayed performance
was moderated by age for items [slope: g =214.75 (95% CI:230.38, 0.88),
t(84.9) = 21.88, P = 0.064] and ordered pairs [slope: g = 213.68 (95% CI:
228.89), 1.52, t(89.1) = 21.79, P = 0.077]. The largest improvement in
elicited imitation delayed performance occurred in the young choline group
(2.5- to #4.0-y-olds). (A) Percentages of individual items recalled. (B)
Percentages of ordered pairs recalled. Choline: n = 30 (young: n = 16;
old: n = 14); placebo: n = 29 (young: n = 13; old: n = 16).
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(2.5- to #4.0-y-olds) showed greater improvement than older
participants (.4.0–5.0-y-olds) did, although there are caveats to
interpreting these findings as will be discussed. Young partici-
pants in the choline arm showed an increase of 12–14 percent-
age points greater than in the placebo arm in long-delay memory
after 9 mo of supplementation, which was a potentially mean-
ingful improvement. Although we could not characterize the
clinical significance of this memory improvement (there are no
normative standards for this measure), we do know that an EI
performance change is expected in this age range (35), and an EI
improvement has implications for future cognitive ability. For
example, in one longitudinal study, EI performance at 20 mo of
age predicted #37% of the variance in explicit memory skill at
6 y of age (37).
In the current study, the effect of choline was seen in the
secondary outcome measure (EI delayed memory performance)
but not in the primary outcomemeasure (global cognitive ability).
Note that, although EI was the secondary outcome measure, it
was considered from the start to be a critical outcome measure
because of choline’s presumed effects on hippocampal de-
velopment [see Wozniak et al. (21)]. Cognitive deficits are
common in FASDs even when a patient’s intelligence quotient is
average (44), which suggests that individual neural systems
(e.g., hippocampus) may be the most-appropriate targets for an
intervention rather than global cognition. The hippocampus is
heavily interconnected with other systems (45, 46), and its in-
tegrity is critical to the development, functioning, and orga-
nization of other domains. Future studies may examine
downstream effects of choline on other domains affected in
FASDs (e.g., attention, executive function, and behavior
regulation).
The observed interaction between choline’s effect on memory
and younger age was consistent with the potential underlying
mechanisms of choline and with existing preclinical data. Pre-
natally, choline affects neurogenesis, thereby contributing to
increased cell proliferation and decreased apoptosis in the hip-
pocampus (47, 48). Postnatal choline may affect synaptogenesis
as well as continued hippocampal growth (49), which is rapid
during the first 2 y of life and slower thereafter (50). In humans,
the hippocampus continues to develop into the fourth year of
life (51). In preclinical models, both early supplementation (post-
natal days 11–20) and late supplementation (postnatal days 21–
30) attenuate cognitive deficits from prenatal alcohol with an
advantage for early supplementation (43). The current human
results suggest that the specific benefits for delayed sequential
memory in FASDs are evident in the first 2–3 y of life, but our
results were less conclusive for older children; we observed
TABLE 4
Simple slope results by age group for performance on the elicited imitation delayed condition1
Choline (n = 30), g 6 SE Placebo (n = 29), g 6 SE t test [t(28), P] Effect size, d
Delayed condition
Items
Young 14.24 6 3.84 4.43 6 4.04 22.41, 0.023 0.54
Old 20.71 6 3.98 4.23 6 3.90 1.21, 0.235 —
Ordered pairs
Young 18.97 6 3.65 10.39 6 4.00 22.18, 0.038 0.50
Old 2.69 6 3.79 7.79 6 3.73 1.31, 0.201 —
Immediate condition
Items
Young 8.48 6 4.23 13.72 6 4.41 1.18, 0.125 —
Old 2.59 6 4.36 3.89 6 4.24 0.29, 0.386 —
Ordered pairs
Young 8.75 6 4.45 20.01 6 4.80 2.36, 0.013 20.46
Old 11.46 6 4.61 5.50 6 4.46 21.27, 0.107 —
1The simple slope was used to estimate the change in delayed performance (%) per 6-mo unit of treatment. The change
over 9 mo of treatment can be computed as 1.5 times the change per 6 mo of treatment.
FIGURE 3 Treatment effect on elicited imitation immediate perfor-
mance. Choline was not associated with the immediate score for items [in-
tercept: g = 211.06 (95% CI: 232.31, 10.19), t(105) = 21.03, P = 0.304;
slope: g = 3.94 (95% CI: 213.19, 21.08), t(86.6) = 0.46, P = 0.649]. A trend
was seen for immediate ordered pairs [intercept: g = 219.14 (95% CI:
240.43, 2.15), t(119) = 21.78, P = 0.078; slope: g = 17.23 (95% CI:
20.97, 35.42), t(93.2) = 1.88, P = 0.063]. (A) Percentages of individual
items recalled. (B) Percentages of ordered pairs recalled. Choline: n = 30
(young: n = 16; old: n = 14); placebo: n = 29 (young: n = 13; old: n = 16).
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a potential ceiling effect in the EI data from the 4–5-y-olds (this
was also evident in the younger group) that may have masked
treatment effects in the older group. Also, we reiterate that the
initial random assignment was not stratified by age; instead, the
sample was evaluated for age interactions and was eventually
split by age after data collection. For these reasons, an additional
examination of choline’s potential in 4–5-y-olds may be war-
ranted in future studies.
There are other important caveats to consider. Despite random
assignment, there was a significant interaction between age and
treatment group (P = 0.046), with the young choline group
having slightly lower delayed EI performance than the other
groups did for items at baseline. The regression to the mean
could have contributed to the young choline group showing the
largest improvement as opposed to the effect being purely
a treatment effect. Another caveat to consider is that item scores
were in the 80–90% correct range at the final study visit, which
suggested a potential ceiling effect. Together, these factors likely
contributed to the observed treatment effect. In a future choline
study, the task difficulty could be increased to better evaluate the
full potential range of choline’s effects.
In the current data, the effect of choline on EI delayed perfor-
mance depended on controlling for the child’s concurrent EI im-
mediate performance, which we believed to be largely a function
of the child’s attention and initial encoding. There is some evi-
dence in the literature that prenatal choline supplementation has
the potential to improve certain aspects of attention (52). The re-
lation between postnatal choline supplementation and attentional
capacity in the context of prenatal alcohol exposure is less clear.
Choline was expected to improve long-term memory storage and
retrieval processes that were measured in the delayed EI con-
dition because choline’s mechanisms of action are in the hip-
pocampus and choline typically improves long-delay memory.
This was the observed pattern for the recall of individual items.
Choline’s effects on immediate memory were harder to predict
on the basis of the existing literature, but there was some reason
to believe that choline could also improve it. In fact, choline did
not affect EI immediate performance for items but did improve
delayed EI performance for items, which suggested that the
effect of choline supplementation is specific to long-delay memory
and that controlling for immediate performance may be warranted.
However, for EI delayed ordered pairs, the results were more
complex. Post hoc analyses suggested that choline may have
a negative effect on immediate memory for ordered pairs. Although
both treatment arms showed an improvement in immediate per-
formance for ordered pairs during the 9 mo of the study, choline
supplementation slightly attenuated this growth for ordered pairs.
Thus, choline’s effects may be multifaceted, and future studies will
need to carefully assess for unexpected changes of this type in
nondelay aspects of memory performance.
Data from the current study may influence future choline
dosing in studies of children with FASDs. The adequate intake is
200 mg for ages 1–3 y and 250 mg for ages 4–8 y (53). On
average, children with FASDs consume insufficient amounts of
choline (54). In the current study, the 500-mg dose was selected
to bring all participants to sufficiency, to provide supplementa-
tion, and to keep amounts in the tolerable range of 1000 mg/d
(53). The 500-mg dose substantially raised free serum choline
and betaine concentrations. Many subjects in the choline arm
(52%) experienced an adverse event of a fishy odor. This event
occurred across the dosage range for body weight (mg/kg) but
was universal (100%) at the highest dosage. The dosage data
showed an inverse relation with memory performance, but there
are caveats to consider. Differential doses were not assigned.
Rather, because the allocated dose was universal, the individual
dosage varied as a function of body weight and compliance (the
majority of variance was due to body weight). The measure with
which dosage was most associated (EI delayed items) ap-
proached a ceiling at baseline and at 9 mo. This effect may have
exaggerated the inverse relation between the dose and treatment
response. There was no relation between the dose and delayed
EI ordered pairs score (for which there was no ceiling effect).
FIGURE 4 Lower daily dose of choline was associated with a greater
treatment effect of choline for elicited imitation delayed items [slope: g =
20.82 (95% CI: 21.60, 20.04), t(34.9) = 22.13, P = 0.041) (A) but not for
ordered pairs [slope: g =20.30 (95% CI:21.10, 0.49), t(36.6) =20.77, P =
0.446] (B). The daily dose was not associated with the intercept for elicited
imitation delayed items (P = 0.152) or for ordered pairs (P = 0.343). Choline
group (n = 25)—10–19 mg/kg: n = 6; 20–26 mg/kg: n = 6; 27–33 mg/kg: n = 7;
and 35–42 mg/kg: n = 6.
FIGURE 5 Prevalence of fishy body odor was greater in the highest
quartile for the choline dose than in the lower 3 quartiles for the choline dose
(P = 0.020; Fisher’s exact test). There were no differences in the presence of
a fishy odor between the lowest 3 quartiles for the choline dose. Choline
group (n = 25)—10–19 mg/kg: n = 6; 20–26 mg/kg: n = 6; 27–33 mg/kg: n = 7;
and 35–42 mg/kg: n = 6.
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For these reasons, the observed relation between the dosage and
outcomes needs to be considered tentative and replicated ac-
cordingly. Nonetheless, these data, together with the side-effect
data, suggest that supplementation with choline beyond the
recommended adequate intake for treatment purposes should
take into account the child’s weight.
The only adverse event that occurred differentially in the
choline arm was a fishy odor. The odor was from trimethylamine,
which is formed when choline becomes available to gut bacteria
(28). Trimethylamine is converted to TMAO in the liver. We
observed significant elevations in serum TMAO concentrations in
the choline arm. In rodent models, increased plasma concen-
trations of TMAO have been suggested as a potential contributor
to atherosclerosis (55). Atherosclerosis-prone (apolipoprotein E–
negative) mice fed choline or TMAO showed greater aortic root
atherosclerotic plaque (56). TMAO concentrations are also as-
sociated with acute cardiovascular events in cardiac patients (56,
57). However, it is not known whether TMAO “has a direct
effect on pathogenesis, is an epiphenomenal biomarker, or is
a precursor to a more direct effector” (58). One study in ham-
sters showed an inverse relation between plasma TMAO and
atherosclerosis (59). Furthermore, fish is a rich source of tri-
methylamine (60), but dietary fish intake is associated with
decreased risk of cardiovascular disease (61). Practically
speaking, smaller choline doses given multiple times per day
(instead of a single bolus) will reduce or eliminate trimethyl-
amine formation, thereby allowing for the potential management
of this adverse effect in future studies.
Additional studies are needed to determine the optimal dosage
that improves memory performance and minimizes the fishy odor
and TMAO increase. Longitudinal studies will determine the
permanency of choline’s effects. Furthermore, the minimum
adequate length of treatment has yet to be established because
the current study tested only the 9-mo duration as a starting
point in this line of research.
In conclusion, this pilot study suggests that an additional
evaluation of choline as a potential intervention for memory
functioning may be warranted in children with FASDs. The
results of the trial are encouraging because, to our knowledge,
there have been no other intervention studies that have shown
similar effects in FASDs nor are there other promising biological
interventions ready for human clinical trials.
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